Kanada - enska - Health Canada

pharmascience inc - bosentan (bosentan monohydrate) - tablet - 125mg - bosentan (bosentan monohydrate) 125mg - vasodilating agents

Bandaríkin - enska - NLM (National Library of Medicine)

cipla usa inc. - bosentan (unii: q326023r30) (bosentan anhydrous - unii:xul93r30k2) - bosentan tablets are indicated for the treatment of pulmonary arterial hypertension (pah) (who group 1): -   in adults to improve exercise ability and to decrease clinical worsening. studies establishing effectiveness included predominantly patients with who functional class ii-iv symptoms and etiologies of idiopathic or heritable pah (60%), pah associated with connective tissue diseases (21%), and pah associated with congenital heart disease with left-to-right shunts (18%) [see clinical studies (14.1)] . use of bosentan tablet is contraindicated in females who are or may become pregnant. to prevent pregnancy, females of reproductive potential must use two reliable forms of contraception during treatment and for one month after stopping bosentan tablets [see boxed warning, warnings and precautions (5.2), drug interactions (7.2), use in specific populations (8.1)].   co-administration of cyclosporine a and bosentan resulted in markedly increased plasma concentrations of bosentan. therefore, concomitant use of

Ástralía - enska - Department of Health (Therapeutic Goods Administration)

sun pharma anz pty ltd - bosentan monohydrate, quantity: 64.541 mg - tablet, film coated - excipient ingredients: glycerol dibehenate; povidone; pregelatinised maize starch; sodium starch glycollate type a; magnesium stearate; maize starch; titanium dioxide; hypromellose; purified talc; triacetin; iron oxide yellow; iron oxide red; ethylcellulose - bosentan is indicated for the treatment of,? idiopathic pulmonary arterial hypertension,? familial pulmonary arterial hypertension,? pulmonary arterial hypertension associated with scleroderma or,? pulmonary arterial hypertension associated with congenital systemic to pulmonary shunts including eisenmenger?s physiology,in patients with who functional class ii, iii or iv symptoms

Ástralía - enska - Department of Health (Therapeutic Goods Administration)

sun pharma anz pty ltd - bosentan monohydrate, quantity: 129.083 mg - tablet, film coated - excipient ingredients: sodium starch glycollate type a; pregelatinised maize starch; povidone; magnesium stearate; glycerol dibehenate; maize starch; titanium dioxide; hypromellose; purified talc; triacetin; iron oxide yellow; iron oxide red; ethylcellulose - bosentan is indicated for the treatment of,? idiopathic pulmonary arterial hypertension,? familial pulmonary arterial hypertension,? pulmonary arterial hypertension associated with scleroderma or,? pulmonary arterial hypertension associated with congenital systemic to pulmonary shunts including eisenmenger?s physiology,in patients with who functional class ii, iii or iv symptoms

Ástralía - enska - Department of Health (Therapeutic Goods Administration)

sun pharma anz pty ltd - bosentan monohydrate, quantity: 64.541 mg - tablet, film coated - excipient ingredients: sodium starch glycollate type a; povidone; magnesium stearate; maize starch; glycerol dibehenate; pregelatinised maize starch; titanium dioxide; hypromellose; purified talc; triacetin; iron oxide yellow; iron oxide red; ethylcellulose - bosentan is indicated for the treatment of,? idiopathic pulmonary arterial hypertension,? familial pulmonary arterial hypertension,? pulmonary arterial hypertension associated with scleroderma or,? pulmonary arterial hypertension associated with congenital systemic to pulmonary shunts including eisenmenger?s physiology,in patients with who functional class ii, iii or iv symptoms

Ástralía - enska - Department of Health (Therapeutic Goods Administration)

sun pharma anz pty ltd - bosentan monohydrate, quantity: 129.083 mg - tablet, film coated - excipient ingredients: pregelatinised maize starch; sodium starch glycollate type a; maize starch; magnesium stearate; povidone; glycerol dibehenate; titanium dioxide; hypromellose; purified talc; triacetin; iron oxide yellow; iron oxide red; ethylcellulose - bosentan is indicated for the treatment of,? idiopathic pulmonary arterial hypertension,? familial pulmonary arterial hypertension,? pulmonary arterial hypertension associated with scleroderma or,? pulmonary arterial hypertension associated with congenital systemic to pulmonary shunts including eisenmenger?s physiology,in patients with who functional class ii, iii or iv symptoms

Ástralía - enska - Department of Health (Therapeutic Goods Administration)

sun pharma anz pty ltd - bosentan monohydrate, quantity: 129.083 mg - tablet, film coated - excipient ingredients: pregelatinised maize starch; magnesium stearate; maize starch; povidone; sodium starch glycollate type a; glycerol dibehenate; titanium dioxide; hypromellose; purified talc; triacetin; iron oxide yellow; iron oxide red; ethylcellulose - bosentan is indicated for the treatment of,? idiopathic pulmonary arterial hypertension,? familial pulmonary arterial hypertension,? pulmonary arterial hypertension associated with scleroderma or,? pulmonary arterial hypertension associated with congenital systemic to pulmonary shunts including eisenmenger?s physiology,in patients with who functional class ii, iii or iv symptoms

Ástralía - enska - Department of Health (Therapeutic Goods Administration)

sun pharma anz pty ltd - bosentan monohydrate, quantity: 64.541 mg - tablet, film coated - excipient ingredients: maize starch; glycerol dibehenate; povidone; pregelatinised maize starch; sodium starch glycollate type a; magnesium stearate; titanium dioxide; hypromellose; purified talc; triacetin; iron oxide yellow; iron oxide red; ethylcellulose - bosentan is indicated for the treatment of,? idiopathic pulmonary arterial hypertension,? familial pulmonary arterial hypertension,? pulmonary arterial hypertension associated with scleroderma or,? pulmonary arterial hypertension associated with congenital systemic to pulmonary shunts including eisenmenger?s physiology,in patients with who functional class ii, iii or iv symptoms

Kanada - enska - Health Canada

accord healthcare inc - bosentan (bosentan monohydrate) - tablet - 125mg - bosentan (bosentan monohydrate) 125mg - vasodilating agents

Kanada - enska - Health Canada

actelion pharmaceuticals ltd - bosentan (bosentan monohydrate) - tablet - 62.5mg - bosentan (bosentan monohydrate) 62.5mg - vasodilating agents